LineaBio submits Drug Master File for Linea 1 GMP iPSC line to U.S. Food and Drug Administration
November 20, 2024 (Toronto, Ontario) – LineaBio, a cell line company, today announced it has submitted a Type II Drug Master File (DMF) to the U.S. Food and Drug Administration (FDA) for its flagship unmodified, off-the-shelf, Good Manufacturing Practices (GMP)-compliant induced pluripotent stem cell (iPSC) line, Linea 1. LineaBio was launched in 2023 by parent companies CCRM, […]